论文信息 - Imatinib and methylprednisolone alternated with chemotherapy improve the outcome of elderly patients with Philadelphia-positive acute lymphoblastic leukemia: results of the GRAALL AFR09 study - 字舞流文

Imatinib and methylprednisolone alternated with chemotherapy improve the outcome of elderly patients with Philadelphia-positive acute lymphoblastic leukemia: results of the GRAALL AFR09 study

H. Dombret | A. Delannoy | M. Béné | P. Berthaud | X. Thomas | D. Coso | O. Legrand | O. Reman | A. Buzyn | E. Delabesse | E. Raffoux | C. Fohrer | F. Rigal‐Huguet | F. Garban | A. Sonet | M. Delain | P. Turlure | C. Bilhou-Nabera | V. Dubruille | S. Castaigne | F. Isnard | S. Bologna | S. Caillères | V. Lhéritier | P. Raby | S. Darré | V. Lheritier | for the Study Alliance Leukemia | F. Rigal-huguet | É. Delabesse | A. Delannoy

[1] D. Hoelzer,et al. Treatment of adult acute lymphoblastic leukemia. , 1999, Hematology. American Society of Hematology. Education Program.

[2] H. Gschaidmeier,et al. A Randomized Phase II Study of Single-Agent Imatinib Versus Chemotherapy Therapy in Elderly Patients with Philadelphia-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Including Analysis of Resistance Patterns. , 2005 .

[3] G. Specchia,et al. Significant reduction of the hybrid BCR/ABL transcripts after induction and consolidation therapy is a powerful predictor of treatment response in adult Philadelphia-positive acute lymphoblastic leukemia , 2005, Leukemia.

[4] T. Naoe,et al. Combination of intensive chemotherapy and imatinib can rapidly induce high-quality complete remission for a majority of patients with newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia. , 2004, Blood.

[5] M. Baccarani,et al. Dramatic Improvement in CR Rate and CR Duration with Imatinib in Adult and Elderly Ph+ ALL Patients: Results of the GIMEMA Prospective Study LAL0201. , 2004 .

[6] M. C. Popescu,et al. Human Autologous Tumor-Specific T-Cell Responses Induced by Liposome Encapsulated Lymphoma Membrane Proteins. , 2004 .

[7] R. Houot,et al. Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia in the Elderly: Prognostic Factors and Treatment Outcome , 2004, Hematology.

[8] Steven M Kornblau,et al. Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate. , 2004, Blood.

[9] H. Gschaidmeier,et al. Early minimal residual disease (MRD) analysis during treatment of Philadelphia chromosome/Bcr-Abl-positive acute lymphoblastic leukemia with the Abl-tyrosine kinase inhibitor imatinib (STI571). , 2003, Blood.

[10] J. Bourhis,et al. Outcome of treatment in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia--results of the prospective multicenter LALA-94 trial. , 2002, Blood.

[11] Sante Tura,et al. A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias. , 2002, Blood.

[12] R. Bouabdallah,et al. Treatment of Acute Lymphoblastic Leukemia in the Elderly: An Evaluation of Interferon Alpha Given as a Single Agent After Complete Remission , 2002, Leukemia & lymphoma.

[13] B. Druker,et al. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. , 2000, The Journal of pharmacology and experimental therapeutics.

[14] Cytogenetic abnormalities in adult acute lymphoblastic leukemia: correlations with hematologic findings outcome. A Collaborative Study of the Group Français de Cytogénétique Hématologique. , 1996, Blood.

[15] E. Kaplan,et al. Nonparametric Estimation from Incomplete Observations , 1958 .